In 29 patients undergoing percutaneous coronary intervention (PCI), we obtained blood samples at baseline, 10 minutes after standard weight-based abciximab (n=15) or double-bolus eptifibatide (n=14) and 5 minutes after unfractionated heparin (UFH; 70 U/kg bolus). The median percent inhibition was significantly higher in the eptifibatide group compared with the abciximab group both before (96.5% [94-100] vs. 85% [77-89.5] [adenosine diphosphate; ADP]; 89.5% [84-95] vs. 59% [37.5-76.5] [thrombin receptor agonist peptide; TRAP], p<0.001 for both) and after UFH (95% [93-100] vs. 79% [68.8-87.5] [ADP]; 82% [77-93] vs. 51% [34.5-71.3] [TRAP], p<0.001 for both). Addition of UFH significantly reduced platelet inhibition in the abciximab group (85% [77-89.5] vs. 79% [68.8-87.5] [ADP]; 59% [37.5-76.5] vs. 51% [34.5-71.3] [TRAP], p<0.05 for both) but not in the eptifibatide group (96.5% [94-100] vs. 95% [93-100] [ADP]; 89.5% [84-95] vs. 82% [77-93] [TRAP], p=ns for both). Eptifibatide achieved superior platelet inhibition before but especially after UFH compared with abciximab.
-
【Unfractionated heparin reduces the anti-platelet effects of abciximab but not eptifibatide during PCI.].
【普通肝素可降低PCI期间阿昔单抗的抗血小板作用，但不会降低依替巴肽的抗血小板作用。】
复制标题
收藏
DOI：10.1177/1076029606293432文章类型：杂志文章
复制DOI
译文
在29例接受经皮冠状动脉介入治疗 (PCI) 的患者中，我们在基线，基于标准体重的阿昔单抗 (n = 15) 或双推注eptifibatide (n = 14) 后10分钟和普通肝素 (UFH; 70 U/kg推注) 后5分钟获得了血液样本。与阿昔单抗组相比，依替巴肽组的中位抑制百分比均显着更高 (96.5% [94-100] vs. 85% [77-89.5] [二磷酸腺苷; ADP]; 89.5% [84-95] vs. 59% [37.5-76.5] [凝血酶受体激动剂肽; TRAP]，p<0.001) 和UFH之后 (95% [93-100] 对79% [68.8-87.5] [ADP]; 82% [77-93] 对51% [34.5-71.3] [TRAP]，p<0.001)。添加UFH可显着降低阿昔单抗组的血小板抑制作用 (85% [77-89.5] vs. 79% [68.8-87.5] [ADP]; 59% [37.5-76.5] vs. 51% [34.5-71.3] [TRAP]，p<0.05)，但在依替巴肽组中没有 (96.5% [94-100] 对95% [93-100] [ADP]; 89.5% [84-95] 对82% [77-93] [TRAP]，p = ns)。与阿昔单抗相比，依替非巴肽在UFH之前 (尤其是在UFH之后) 获得了更好的血小板抑制作用。
